Health Condition 1: F411- Generalized anxiety disorder
Conditions
Interventions
Intervention1: Vortioxetine: Vortioxetine (10mg-20mg) will be given and
1. Patients will be assessed by Digit Symbol Substitution Test at baseline, week 4 and week 8.
2. Patients will be assessed usin
Sponsors
Mitsha Nagpal
Riya Shetty
Eligibility
Inclusion criteria
Inclusion criteria: 1. Both male and female patients aged between 18 and 60 years. 2. Those giving written consent/guardians giving written consent (in cases where the patients were too ill to understand the process of informed consent and give an informed choice.) 3. People diagnosed with anxiety disorder as per ICD-10 diagnostic criteria. 4. HAM-A score =18
Exclusion criteria
Exclusion criteria: 1. Systemic or Neurological Disorder affecting Cognition, Behavior or Mental Status. 2. Substance dependence except for Nicotine and Caffeine within the past month of entering the study. 3. Long-standing medical or surgical illnesses. 4. Patients with mental retardation or organic brain disorders. 5. Patients suffering from neurological, metabolic and vascular conditions affecting sexual function.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Vortioxetine will be more efficacious on symptom severity in patients suffering from Anxiety Disorder compared to Sertraline.Timepoint: At the end of 4 weeks and 8 weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| Vortioxetine and Sertraline will have similar effects on cognitive functioning.Timepoint: At the end of 4 weeks and 8 weeks.;Vortioxetine and Sertraline will have similar side effects.Timepoint: At the end of 4 weeks and 8 weeks.;Vortioxetine will be safer as compared to Sertraline in sexual functioning.Timepoint: At the end of 4 weeks and 8 weeks. | — |
Countries
India
Contacts
Public ContactKritika Agarwal
IMS & SUM Hospital
Outcome results
None listed